Baseline characteristics of study subjects who withdrew from the study or were lost to followup (n = 9). Values are mean (SD) or median (interquartile range) unless otherwise specified.
| Clinical Characteristics | Values, n = 9 |
|---|---|
| Age, yrs | 63.2 (14.5) |
| RA disease duration, yrs | 13 (14.3) |
| Female, n (%) | 9 (100.0) |
| White, n (%) | 7 (77.8) |
| RF/CCP-positive, n (%) | 2 (22.2) |
| DMARD use, n (%) | |
| Nonbiologic | 3 (33.3) |
| Biologic | 5 (55.6) |
| Oral glucocorticoid use, n (%) | 1 (11.1) |
| Meets ACR 2010 criteria, n (%) | 5 (55.6) |
| SJC | 1 (0.0–1.0) |
| TJC | 8 (3.0–17.0) |
| CRP | 1.9 (1.0–3.9) |
| DAS28-CRP | 3.3 (3.1–4.6) |
| Tender point count | 11 (2.0–16.0) |
| HADS anxiety score | 5.4 (5) |
| HADS depression score | 3.2 (2) |
| Medical Outcomes Study Sleep Problems | |
| Index II score | 42.5 (17.7) |
| Pain Catastrophizing Scale score | 25.8 (9.2) |
RA: rheumatoid arthritis; RF: rheumatoid factor; CCP: cyclic citrullinated peptide; DMARD: disease-modifying antirheumatic drug; ACR: American College of Rheumatology; SJC: swollen joint count; TJC: tender joint count; CRP: C-reactive protein; DAS28: Disease Activity Score at 28 joints; HADS: Hospital Anxiety and Depression Scale.